Phase II Study of an ‘All-Oral’ Regimen of Capecitabine, Idarubicin and Cyclophosphamide for Metastatic Breast Cancer – Safety, Efficacy and Quality of Life

Publisher： Karger

E-ISSN： 1423-0232|68|4-6|520-525

ISSN： 0030-2414

Source： Oncology, Vol.68, Iss.4-6, 2005-08, pp. : 520-525

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

By  

Oncology, Vol. 71, Iss. 1-2, 2007-04 ,pp. : 54-60

Karger

Access to resources Recommend Favorite

Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer

By  

Oncology, Vol. 72, Iss. 5-6, 2008-01 ,pp. : 330-337

Karger

Access to resources Recommend Favorite

Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study

By  

Oncology Research and Treatment, Vol. 37, Iss. 12, 2014-11 ,pp. : 748-755

Karger

Access to resources Recommend Favorite

Capecitabine for the oral treatment of metastatic breast cancer

By Cortés-Funes Hernán  

Women's Health, Vol. 2, Iss. 6, 2006-11 ,pp. : 805-817

Future Medicine

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 190-195

Karger

Access to resources Recommend Favorite